Biotechnology
100 Billion Live Probiotics in a Bottle: TCI JAPAN Launched its Breakthrough, SCIENCE OF PROBIOTICS, After 20 Years of Research
TAIPEI, June 23, 2021 /PRNewswire/ -- Probiotic drinks now available on the market often cannot fully exert the effect despite the content of lactic acid bacteria because live bacteria in thedrinks can be killed over time or due to poor storage, which causes the numbers of live probiotics consume...
2021-06-23 14:28
1546
Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars
BEIJING and BOSTON, June 22, 2021 /PRNewswire/ -- Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically engineered animal models, today announced the successful completion of a new round of financing totaling tens o...
2021-06-23 04:16
1544
Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia
SHENZHEN, China, June 22, 2021 /PRNewswire/ -- On June 21, local time, phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was officially initiated inMalaysia, and the first batch ...
2021-06-22 22:32
9433
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.
NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL...
2021-06-20 21:00
2864
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma
BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib atthe 16th International Conf...
2021-06-18 17:12
13763
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...
2021-06-17 15:41
13817
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma
BEIJING, June 16, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its pan-FGFR inhibitor gunagratinib (ICP-192) ...
2021-06-17 11:31
14155
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer t...
2021-06-16 13:08
8454
Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci
SHANGHAI, June 15, 2021 /PRNewswire/ -- Viva Biotech (01873.HK) declared today that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. Totient is a biotech company, harnessing human ...
2021-06-16 10:14
22642
BIO Digital Taiwan Day will be held on June 22
TAIPEI, June 15, 2021 /PRNewswire/ -- With COVID-19 dramatically changing the healthcare industry, organizations have been forced to adapt their practices and embrace digital transformation - and now, as vaccines become more available in the developed countries, it is time to look into the future...
2021-06-15 23:00
1694
The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
SHANGHAI, June 14, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...
2021-06-15 08:46
1333
Happiness Biotech Signed Agreement To Distribute Volkswagen Electric Vehicles
NANPING, China, June 14, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer and e-commerce services provider, announced today that Taochejun (Fujian) Automobile Distribution Co., Ltd. ("Taoc...
2021-06-14 20:00
10999
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis
SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293). Th...
2021-06-14 06:00
2120
OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management
SEOUL, South Korea, June 10, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that it is expanding its Scientific Advisory Board ("SAB") for SCN9A antisense pain killer OLP-1002 to include ProfessorPatrick M. Do...
2021-06-10 21:00
1367
Travecta Therapeutics Appoints Charles S. Ryan as President and Chief Executive Officer
SINGAPORE, June 9, 2021 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced the appointment ofCharles S. Ryan, JD, PhD as President and Chief Execut...
2021-06-09 21:00
1571
Cell Care Joins the Generate Life Sciences Family to Create a Global Platform
The acquisition provides the companies with shared scientific knowledge and resources leading to a stronger foundation for advancing newborn stem cell banking and research MELBOURNE, Australia, June 3, 2021 /PRNewswire/ -- Cell Care, Australia's leading cord blood bank, today announced it has be...
2021-06-03 06:00
2194
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb®...
2021-06-02 21:00
8937
Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs
SUZHOU, China, June 2, 2021 /PRNewswire/ -- On May 31, 2021, Porton Biologics Ltd. (hereinafter referred to as Portonbio) announced a strategic cooperation with Nanjing KAEDI Biotech, Inc. (hereinafter referred to as KAEDI).Portonbio will offer CMC services for KAEDI's CAR-T cell therapies with i...
2021-06-02 20:10
1636
PharmAbcine to Present at the BIO Digital International Convention 2021
DAEJEON, South Korea, June 2, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will participate in BIO Digital International Convention. The company will participate in...
2021-06-02 20:00
2283
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment...
2021-06-02 19:00
1422
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5203
